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Case presentation
A 38-year-old woman was admitted to the New England Medi-
cal Center Hospital (NEMCH) 4 years ago with a 10-year history
of intermittent fatigue, arthralgias, oral ulcers, pleurisy, and a
photosensitive facial rash. Blood pressure was 140/80 mm Hg,
and physical examination revealed a malar rash, peripheral
adenopathy, and splenomegaly. Serologic studies revealed an
anti-DNA titer of 24. mg/mi (normal < 2.5 mg/ml), a total
serum hemolytic complement (CH50) of 58 units (normal > 50
units), and a C3 of 0.32 mglml (normal .87 to 2.2). Urinalysis
showed 3 + protein; 1 + blood; and 10 to 15 white blood cells and
2 to 4 red blood cells per high-power field. The 24-hour urine
protein excretion was 1.3 g. Serum creatinine was 0.8 mg/dl.
The patient was treated initially with 40 mg of prednisone dai-
ly, but the serum complement levels remained depressed. Her
blood pressure rose to 180/110 mm Hg, and treatment with hy-
drochlorothiazide was initiated. She tolerated prednisone poor-
ly, developing mood changes and Cushingoid features. The dose
of prednisone was gradually reduced to 10 mg per day over a 6-
month period. She continued to have intermittent pleuritic chest
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pain and arthralgias. Three and one-half years ago treatment with
azathioprine was initiated at a dose of 100 mg/day.
Approximately 3 years ago, the serum creatinine was 1.7 mg/
dl. Urinalysis showed 2+ protein with 5 to 6 white blood cells
and 10 to 20 red blood cells per high-power field. Prednisone was
increased to 60 mg per day. Diastolic blood pressures remained
in the range of 110 to 120 mm Hg; propranolol, hydralazine, and
furosemide were added to her therapeutic regimen. The dose of
azathioprine was increased transiently to 150 mg per day but had
to be lowered to 50 mg per day because of leukopenia. During the
ensuing 6 months, the serum creatinine rose progressively to 2.7
mg/dl and the 24-hour urinary protein excretion increased to 6 to
7 g. By the end of that 6-month period, azathioprine was discon-
tinued and the patient was treated with 60 mg of cyclophospha-
mide.
She was readmitted to the NEMCH 2.5 years ago with a blood
pressure of 230/130 mm Hg and anasarca. The serum creatinine
was 1.9 mg/dl, the 24-hour urine protein excretion was 10.4 g,
and the serum albumin was 2.4 g/dl. Blood pressure was con-
trolled with the addition of alpha-methyldopa and intravenous
furosemide to the therapeutic regimen. Prednisone was in-
creased to 100 mg per day. Cyclophosphamide was discontinued
because the anti-DNA titer and CH50 had returned to the normal
range. A percutaneous renal biopsy was performed.
During the subsequent 3 months, the patient developed a se-
vere proximal myopathy, marked Cushingoid features, and
osteoporosis complicated by a thoracic vertebral compression
fracture. The dose of prednisone was gradually tapered again.
For the next 2 years, her blood pressure was well controlled de-
spite an intolerance to many antihypertensive medications and
the patient's noncompliance in taking them. Renal function re-
mained stable; serum creatinine ranged from 2.0 to 2.5 mg/dl.
Anti-DNA titers remained mildly elevated but serum com-
plement levels generally remained in the normal range. One year
ago, prednisone was tapered to 20 mg every other day; however,
treatment with azathioprine was reinstituted because of per-
sistent arthraigias.
She was readmitted to the NEMCH 6 months ago because of
deteriorating renal function and poorly controlled hypertension.
Her blood pressure, which was 240/180 mm Hg on admission,
was controlled by treatment with minoxidil. The serum creati-
nine was 3.5 mg/dl. Urinalysis showed microscopic hematuria
and many red blood cell casts. Prednisone was again increased to
80 mg per day. Azathioprine could not be increased beyond 50
mg per day because of persistent leukopenia. During the next 4
months, her renal function deteriorated further despite 5 one-
liter plasma exchanges performed over 2 weeks. Although high-
dose prednisone therapy was continued, she required hospital-
ization on two later occasions because of acute abdominal pain
secondary to lupus peritonitis. Myopathy recurred and another
vertebral compression fracture developed. Two months ago, the
serum creatinine was 8.5 mg/dl, uremic symptoms appeared, and
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maintenance hemodialysis was initiated. Treatment with azathio-
prine was discontinued and the dose of prednisone was again
tapered. She continues to require minoxidil and propranolol for
control of hypertension.
Discussion
DR. ROBERT S. SCHWARTZ (Chief, Hematology-
Oncology Division, New England Medical Center
Hospital; Director, Cancer Research Center, and
Professor of Medicine, Tufts University School of
Medicine, Boston, Massachusetts): A kidney
biopsy was performed shortly after this patient's
renal function began to deteriorate. What were the
pathologic findings?
DR. VIVIAN PINN (Associate Professor of Pat ho!-
ogy, Tufts University School of Medicine, Boston,
Mass.): The renal biopsy specimen contained ap-
proximately 30 glomeruli, all of which were in-
volved by a moderate to severe degree of mesangial
proliferation. In many instances the entire glomeru-
lus or a segment of it had a lobular appearance (Fig.
1A). Occasional polymorphonuclear leukocytes
were evident within glomerular tufts, and about
one-third of the glomeruli also had epithelial cell
proliferation with localized crescent formation.
Many intracapillary thrombi were present. The gb-
merubar capillary basement membrane was irregu-
larly thickened and some areas exhibited a "wire-
loop" configuration. Foci of interstitial chronic in-
flammatory infiltrates also were present.
Immunofluore scent studies demonstrated irregu-
lar but prominent fine to coarse granular deposition
of immunoglobulins (IgG, 1gM, IgA) with a similar
pattern of deposition of C3, C4, and Clq, pre-
dominantly on the peripheral capillary basement
membrane but also in the mesangium and foci of
Bowman's capsule (Fig. lB). Granular deposits of
IgG and C3 also were identified on the tubular base-
ment membrane.
Electron microscopy confirmed the findings by
light microscopy and showed prominent sub-
endothelial and mesangial electron-dense deposits
with scattered intramembranous and rare intra-
membranous deposits (Fig. lC). Mesangial cell pro-
liferation with increased mesangial matrix often ex-
tended along the peripheral capillary basement
membrane and produced a double contour appear-
ance similar to that seen in membranoproliferative
glomerulonephritis. Epitheliab cells were hyper-
trophied with effacement of foot processes. In sum-
mary, the biopsy demonstrated diffuse proliferative
lupus nephritis with a membranoproliferative gb-
merular pattern.
Fig. 1 A Light microscopy of a glomerulus demonstrating the
accentuated lobular architecture, increased mesangial cells and
matrix, and thickened peripheral capillary loops (x250, hema-
toxylin and eosin). B Photograph of immunofluorescent demon-
stration of IgG deposition in an irregular granular distribution
along peripheral glomerular capillary basement membranes,
Bowman's capsule, and the mesangium (X600).
DR. SCHWARTZ: This woman's medical course
and her biopsy illustrate a classic example of exten-
sive immunologic injury in a patient with systemic
lupus erythematosus (SLE). The autoimmune dis-
ease par excellence, SLE is a disorder with many
challenges for both clinicians and research scien-
tists. The clinician must deal with patients whose
disease can affect any organ, from brain to bowel;
the researcher seeks to unravel the immunologic,
genetic, hormonal, and environmental factors that
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form a matrix of causative events in the disorder.
The clinician must be prepared to distinguish organ-
ic brain disease from a psychiatric disorder, recog-
nize a variety of dermatologic manifestations, treat
hypertension, decide about splenectomy, and deal
with the emotional upheavals of chronically ill pa-
tients who require treatment with potentially toxic
drugs. Researchers must use the concepts and tools
of cellular immunology, immunochemistry, immu-
nopathology, genetics, and even virology and endo-
crinology. Thus, SLE is not a disease for narrow
specialists.
Despite the complexity of SLE, considerable ad-
vances have been made, especially during the past
decade. Data from Dubois [1] and from Fries and
Holman [2] provide the most convincing evidence
of this progress, that is, the dramatic improvement
in prognosis (Fig. 2). In 1950, virtually all patients
with SLE died within 5 years of diagnosis; today,
only about 10% succumb to the disease within that
time. This remarkable change is due to: (1) general
improvements in medical care since 1950; (2) the in-
troduction of specific and sensitive diagnostic tests
for SLE, which have made it possible for us to rec-
ognize the disease in its early stages; and (3) in-
creased sophistication in the application of cortico-
steroid and immunosuppressive therapy. Never-
theless, important clinical problems remain. In-
2 3 4
Years after diagnosis
Fig. 2. Survival in SLE, 1950-1975. Data obtained from Dubois
[II and Fries and Holman [2]. Improved diagnostic tests have led
to the inclusion of earlier and milder cases of SLE, thus adding to
the improved survival.
volvement of the central nervous system and the
kidney continue to be major causes of disability and
death. Diffuse lupus nephritis is still an ominous de-
velopment, and the outlook for patients with this
complication is as poor today as was the general
prognosis for patients with SLE 25 years ago [3]
(Fig. 3).
Several excellent papers offer detailed reviews of
the clinical and serologic features of SLE [4—6]. I
will focus, therefore, on the causative matrix,
which is the centerpiece of current research in SLE.
We will examine the idea that SLE is a genetic ab-
normality of the immune system and that SLE is a
syndrome whose manifestations can arise from dif-
ferent types of genetic abnormalities, all of which
ultimately lead to a common pathogenetic mecha-
nism, namely the deposition of circulating immune
complexes in various tissues.
The best evidence that SLE has a genetic basis is
the high concordance of the disease in monozygotic
twins. Block et al reviewed the cases of 63 patients,
each of whom had an identical twin [7]. The con-
cordance of the disease in this group was 63% (40 of
63), a rate that indicates a strong genetic influence.
This figure of almost two-thirds is actually a mini-
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Fig. 1 C Electron micro graph of a glomerular capillary loop with
prominent subendothelial and mesangial electron-dense depos-
its as well as sparse subepithelial deposits (M = mesangium).
Subendothelial mesangial interposition can be seen at the periph-
ery of the capillary loop (x2800).
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Fig. 3. Influence of lupus nephritis on the prognosis of SLE.
Lines labeled "Kincaid-Smith" were derived from Ref. 3.
mal estimate; the onset of the disease in the twins
was temporally discordant, and additional cases of
concordant disease thus are expected. Another in-
teresting aspect of this survey was the confirmation
of a relatively high incidence of serologic abnormal-
ities in healthy, first-degree relatives of patients
with SLE (Table 1). The difference between
spouses and first-degree relatives in this regard is
highly significant (x2 = 59.5, P < 0.001) and points
to another kind of genetic influence to which I shall
return.
When the disease occurs in twins, clinical mani-
festations tend to be similar in both [7]. In light of
the large number of possible clinical expressions of
the disease, this tendency seems remarkable.
Another set of genetic factors thus appears to in-
fluence the particular way in which patients express
the disease. From these observations, we can con-
Table 1. Evidence for genetic factors in SLEa
ANAb SLE
Monozygotic twins 41/63 (65%) 40/63 (63%)
First-degree relatives 182/1113 (16%) 1/53 ( 2%)
Spouses 36/762 ( 5%) 0/762 ( 0%)
a Data from Ref. 7.
b ANA refers to a positive antinuclear antibody test.
dude that at least three kinds of genetic factors
influence SLE: those that result in clinically overt
disease; those that result in a tendency toward the
formation of autoantibodies, but not toward the
disease; and those that dictate the actual lesions of
the disease.
Genes cannot explain SLE entirely, however. If
this were so, the concordance rate in identical twins
would be 100%. Also, it is well known that females
develop SLE more than males do: a survey of al-
most 1000 patients with SLE disclosed that 90%
were females and that the median age was 28.4
years [1]. Because SLE is a disease of young wom-
en at the peak of their reproductive capacities, we
can deduce that sex hormones profoundly influence
the disease. Experiments from Talal's group sup-
port this conclusion [8, 9]. He and his colleagues
have shown in an animal model of SLE that admin-
istration of estrogens accelerates the development
of lupus nephritis, whereas androgens hinder its de-
velopment. Whether these hormones act on autoan-
tibody-producing cells or whether they influence
the handling of immune complexes by the reti-
culoendothelial system is unknown. However the
effects of these hormones are explained, it is clear
that they affect genetic mechanisms in an important
way. The influence of estrogens on gene expression
is, of course, a well-known phenomenon [10, 11].
The clinical manifestations of SLE are sometimes
not distinctive, but the serologic abnormalities are
its hallmark (Table 2). The patient with SLE pro-
duces numerous kinds of autoantibodies: the most
characteristic of these are the antibodies against nu-
cleic acids, notably antibodies to native and dena-
Table 2. Partial list of autoantibodies found in SLE
Against components of cell nuclei
Native DNA
Denatured DNA
Nucleoprotein
Single-strand RNA
Double-strand RNA
Sm antigen
Oligonucleotides
Against components of cytoplasm
Ribosomes
Lysosomes
Ro antigen
Against cell membranes
Red cells
Platelets
Lymphocytes
Granulocytes
Other
Cardiolipin
Coagulation factors
Membranous LE nephritis
(Kincaid-Smith, 1972)
Diffuse LE nephritis
(Kincaid-Smith, 1972)
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tured DNA. Studies of these antibodies can illus-
trate four important aspects of lupus. First, their
presence is a highly specific diagnostic finding.
Antibodies that bind to native DNA or to the nude-
oprotein Sm antigen are rarely found except in pa-
tients with SLE [12]. Second, some of the serologic
abnormalities provide useful markers by which the
activity of the disease can be measured objectively,
and perhaps even predicted [13]. Antibodies to
DNA and levels of complement activity in the blood
are particularly useful in this regard (Fig. 4). A third
and related aspect is the abundant evidence that
these autoantibodies participate in the pathogenesis
of the lesions of SLE. For example, anti-DNA au-
toantibodies are important constituents of the im-
mune complexes that deposit in the glomerular
basement membranes [4]. Fourth, and currently the
most perplexing aspect of lupus, is the explanation
of how these antibodies originate. It is to this ques-
tion that I would now like to turn.
Contemporary cellular immunology can be sum-
marized in two words: recognition and regulation.
Recognition" refers to those mechanisms where-
by lymphocytes recognize not only foreign struc-
tures, but each other; "regulation" refers to mecha-
nisms that control the immune response. These def-
initions are useful because the cytologic simplicity
of lymphocytes masks the complexity of their func-
tion. Look-alike lymphocytes actually comprise
various subsets, each with different functions.
Three major divisions exist among these subsets:
helper T lymphocytes, suppressor T lymphocytes,
Autoimmune disease
Fig. 5. Suppressor cell theory of SLE. T1 refers to helper T cell,
T5 refers to suppressor T cell. The lines and arrows represent
regulatory loops in schematic form. According to this theory,
defective T5 function unleashes" B cells.
and B lymphocytes. These kinds of cells, together
with macrophages, constitute the primary elements
of the immune system. They are held together in a
functional unit by a network of regulatory signals in
a manner analogous to the web of signals that in-
tegrates the cells of the brain. The lymphocytic sig-
nals, whether they extend from cell surfaces or dif-
fuse through extracellular fluids, are responsible for
both recognition and regulation.
A predominant theory of autoimmunization pro-
poses that impaired regulation of the immune sys-
tem leads to the production of autoantibodies [14].
This theory assumes the existence of B lympho-
cytes that have the potential to produce autoanti-
bodies. This potential normally is not realized be-
cause of the restraining influence of immunoregula-
tory T lymphocytes. According to the most popular
version of this theory, a qualitative or quantitative
defect of suppressor T cells would fail to regulate
potential autoantibody-producing B lymphocytes,
thereby "unleashing" them (Fig. 5).
One recent theory does not require defective im-
munoregulation for autoimmunization. Instead, the
primary disturbance is thought to involve clones of
B lymphocytes that produce autoantibodies despite
normal regulatory signals from T lymphocytes [15].
These B lymphocytes are thus "outlaws" (Fig. 6).
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Fig. 4. Clinical chart of a patient with SLE showing the relation-
ship between activity of the disease and serologic abnormalities.
The inverse relationship between levels of anti-DNA antibodies
(solid line) and levels of hemolytic complement activity (dashed
line) is noteworthy.
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Fig. 6. Outlaw B cell theory of SLE. According to this theory, a
subset of intrinsically abnormal B cells fails to respond to immu-
noregulatory signals and produces autoantibodies.
Fig. 7. Another theory of SLE. According to this view, autoanti-
bodies produced by abnormal B cells impair suppressor T cells,
thereby accelerating the tendency toward autoimmunization.
Recently, Gershwin and his colleagues at the Uni-
versity of California at Davis showed that severe
lupus nephritis developed in the offspring of New
Zealand black and New Zealand white mice [(NZB
X NZW)F] that were homozygous for the gene nu
(personal communication). Homozygosity for this
gene causes congenital absence of the thymus and,
as a consequence, the absence of any mature T
cells. Thus, autoimmunization with the production
of a fatal form of lupus nephritis can occur in ani-
mals whose functioning lymphocytes consist almost
entirely of B cells.
A reconciliation between these contrasting theo-
ries of autoimmunization is shown in Figure 7 and is
based on the finding of autoantibodies to T lym-
phocytes, particularly autoantibodies specific for
suppressor T lymphocytes in SLE [16]. These au-
toantibodies, which could be produced by intrinsi-
cally abnormal ("outlaw") B lymphocytes, might
impair immunoregulatory circuits and thereby re-
cruit into the pathogenetic mechanism additional
autoantibody-producing B lymphocytes. A vicious
cycle arising out of such an immunologic whirlwind
can be envisioned.
Solid data from experiments in animal models of
SLE support each of these theories. The impor-
tance of such animal models to our current under-
standing of the disease cannot be overemphasized.
The most familiar of them is the NZB mouse, a
highly inbred strain in which a lupus syndrome reg-
ularly develops. Recent studies of NZB mice have
shown that their B lymphocytes spontaneously se-
crete large amounts of immunoglobulins [17]. This
so-called spontaneous polyclonal activation of B
cells can be detected even in fetal NZB mice and
occurs independently of any known T-lymphocyte
influence [18]. Not only is immunoglobulin syn-
thesis increased markedly, but the number of immu-
noglobulin-containing cells is also increased. Fur-
thermore, the amount of immunoglobulin secreted
per cell is higher than that found in B lymphocytes
of normal mice. A separate genetic mechanism dic-
tates each of these abnormal properties of NZB im-
munoglobulin-producing cells [18]. For instance,
the number of immunoglobulin-containing cells is a
dominant autosomal trait, whereas the increased se-
cretion rate per cell is controlled by autosomal re-
cessive genes. The abnormal cells represent a dis-
tinct and minor population, which has been traced
to a particular subtype of B lymphocytes [19]. The
remaining B lymphocytes in NZB mice, by con-
trast, seem normal.
Andrews et al have investigated the clinical and
serologic manifestations of SLE in several other ex-
perimental models [20] (Table 3). Each of these in-
bred lines of mice has distinct immunologic, ge-
netic, and hormonal features. Yet each develops
one or more characteristic lesions of SLE. These
various models add to the evidence that SLE is a
syndrome that can result from one of several dif-
ferent pathways. Each inbred strain represents a ge-
netic "window" through which one of the pathways
to lupus can be perceived. It thus would be surpris-
ing if a single mechanism could explain SLE in a
genetically heterogeneous human population. There
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Table 3. Clinical and serologic findings of SLE in 6 highly inbred
strains of mice
Manifestation
Inbred strain
NZB B/W MRL/1 BXSB Me/me Swan
Hemolytic anemia + + + 0 0 + + 0 0
Nephritis
Vasculitis + 0 0 0
Dermatitis 0 0 ++ 0 + + +
Arthritis 0 0 ++ 0 0 0
Anti-DNA anti-
bodies ++ +++
Anti-Sm anti-
bodies 0 0 ++ 0 — —
Anti-lymphocyte
antibodies + + + + + + + +. + + + —
Rhematoid factor 0 0 — —
Each genetically uniform strain presents a distinct lupus syn-
drome. Approximate severity (clinical or pathologic) or levels of
autoantibodies are estimated on a scale from 0 to + + + +. Data
from Ref. 20.
Indicates unknown.
is, therefore, no place for dogmatism in formulating
notions about the etiology of SLE.
None of the current ideas, however, comes to
grips with the serologic abnormalities of SLE. None
of them explains exactly how the patient forms anti-
bodies to DNA. Indeed, all of the current theories
assiduously avoid any mention of this specific fea-
ture of the disease. This neglect is not without
cause: little is known about the immunochemical
specificities of the autoantibodies in SLE. Our igno-
rance of this aspect of SLE stems from the fact that
lupus serum is a complex mixture of antibodies. No
method is available for separating this mixture into
its component parts so that a single molecular spe-
cies of autoantibody can be analyzed. Recently,
however, a powerful technique with exciting possi-
bilities for studies of individual antibodies was de-
vised by Köhler and Milstein [211. This method uti-
lizes somatic cell hybridization to immortalize
single antibody-forming cells by fusing them with
myeloma cells. Such hybridomas, as they are
called, can be cloned and, after either in vitro or in
vivo culture, they produce monoclonal antibodies
that are encoded by genes derived from the anti-
body-producing B lymphocyte partner of the fusion
product. The Köhler and Milstein method has revo-
lutionized immunology because of its analytic pow-
er and its enormous specificity.
My colleagues and I have begun to apply shy-
bridoma technology" to a study of spontaneously
produced autoantibodies to DNA. For this purpose,
we fused spleen cells from unimmunized MRL/1
mice with mouse plasmacytoma cells. The MRL/l
mice develop a severe form of lupus and produce
high levels of autoantibodies to DNA (see Table 3).
The fusion procedure led to the isolation of cloned
hybridomas that secrete single molecular species of
autoantibodies to DNA [22]. These hybridoma au-
toantibodies also have been used to prepare anti-
idiotype antibodies in rabbits. Idiotype" refers to
a structure in the hypervariable region of an immu-
noglobulin molecule that constitutes a portion of its
antigen-binding domain. Such structures would be
specific for a given antibody molecule, and thus
they represent "markers" of exceptional specifici-
ty. The antiidiotypic antisera provide the means by
which these markers can be detected and quan-
titated.
These new reagents already have yielded two im-
portant findings [23]. The first is that monoclonal
autoantibodies to DNA can manifest multiple sero-
logic specificities. For instance, many of the cloned
"anti-DNA" antibodies also bind to several dif-
ferent polynucleotides, including poly(I), poly(G),
and poly(A). This surprising behavior, unexpected
from a single molecular species of antibody, implies
the existence of shared antigenic structures among
a wide variety of nucleic acid antigens; such struc-
tures might reside within the sugar-phosphate back-
bones of DNA and other polynucleotides. This find-
ing also implies that the number of autoantibodies
produced in SLE is less than the number suggested
by the many serologic manifestations of serum from
patients with lupus, because a single species of au-
toantibody can have diverse serologic properties.
The second important finding revealed by the
antiidiotype reagents is the presence of similar
idiotypes among different monoclonal autoanti-
bodies from different individuals. The genes that en-
code these crossreacting structures therefore might
share certain nucleotide sequences. One implica-
tion of this finding is that "families" of related auto-
antibody-encoding genes might exist in the germ
line of MRL/l mice. If this interpretation is borne
out, the fundamental defect in SLE will boil down
to a defect of gene regulation.
Some researchers have used a Mendelian ap-
proach to study the genetics of SLE. Such studies
examine how the phenotypes of the disease segre-
gate among crosses between affected and normal in-
dividuals. The (NZB X NZW)F1 hybrid is a striking
example of the power of this orthodox approach.
Although NZB mice regularly develop autoimmune
hemolytic anemia as part of their lupus complex,
nephritis is rare (Table 3). In striking contrast, se-
vere lupus nephritis develops uniformly in the prog-
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Fig. 8. Development of lupus nephritis in (NZB X NZW) F1 hy-
brid mice (BIW). Neither the NZB nor the NZW parent develops
this disorder. NZB mice have a lupus diathesis, whereas NZW
mice are normal and do not produce autoantibodies or form le-
sions of lupus or any related disorder.
eny of crosses between NZB and NZW mice (a
strain in which lupus never occurs) (Fig. 8) [24]. A
similar event occurs in crosses between NZB and
SWR mice, another normal inbred strain in which
neither autoantibodies nor lupus lesions ever devel-
op [25].
These findings signify that genes possessed by
normal individuals must influence the clinical ex-
pression of the lupus "diathesis." By means of tra-
ditional Mendelian techniques, Knight and Adams
demonstrated in the (NZB X NZW)F1 model that
three genes (or gene complexes) participate in the
development of lupus nephritis, and that two of
these derive from the normal NZW parent [26].
These facts have led to the formulation of a new
theory about the genetics of SLE [27], which pro-
poses the existence of two families or classes of
genes that might be unlinked in the Mendelian
sense. Each family, however, encompasses a set of
functionally related genes (Table 4). The first of
these classes of genes controls the central immune
functions of recognition and regulation. It would en-
compass, for instance, genes that control suppres-
Table 4. Dual gene hypothesis of autoimmune disease
Class I genes (central immune function)
Self recognition
Immune response genes
Immunoregulation (helper and suppressor cells)
Class II genes (peripheral manifestations of immunity)
Immune complexes
Complement
Inflammatory response
sor and helper T-cell function and HLA genes. The
second class of genes specifies the peripheral arm of
the immune system, such as immunoglobulin class
or avidity, the ability to form soluble immune com-
plexes, and the complex set of mechanisms that
comprise the inflammatory response.
Individuals with permissive alleles of only class I
genes could form autoantibodies, but they would
develop no lesions. These individuals would corre-
spond to the healthy autoantibody-producing, first-
degree relatives of patients with SLE, alluded to
previously. Individuals with permissive alleles of
only class II genes would be healthy. They would
be, for instance, the counterparts of NZW or SWR
mice. The patient with SLE inherits permissive al-
leles of both classes of genes. The clinical manifes-
tations of the disease, according to this theory,
would result principally from the actions of particu-
lar class II genes.
Dr. Kenneth Miller and I tested these ideas ex-
perimentally in human SLE [28]. We sought evi-
dence for the existence of permissive alleles of class
I genes by a family study in which we examined
suppressor T-cell function in first-degree relatives
of patients with SLE. The assay system was based
on the ability of the plant lectin concanavalin A to
stimulate the functional development of suppressor
T lymphocytes from a pool of precursor cells. We
assayed these lectin-stimulated suppressor cells in
turn for their ability to suppress the synthesis of IgG
by B lymphocytes. The results demonstrated an im-
pairment of suppressor T-cell function in 13 of 51
clinically healthy, first-degree relatives of patients
with SLE. Also, 12 of these 13 relatives were wom-
en. This finding supports the view that defective im-
munoregulation is a genetic abnormality in SLE and
also supports the argument that defective immuno-
regulation cannot by itself explain the disease, as
the first-degree relatives with the abnormality had
no signs of SLE. We presume that other factors,
such as permissive alleles of class II genes, must
participate in the full expression of this condition.
Our present view of SLE is summarized in Figure
9, which shows the interactions between genetic
factors and the environment in the causation of this
disorder. One may add to this scheme the role of
sex hormones, but the locus of their action is un-
known. We can conclude safely that the cause and
pathogenesis of SLE is better understood today
than ever before. The application of new methods,
such as hybridoma technology, to the analysis of
this disease holds great promise not only because it
ultimately will reveal the molecular biology of
Class I genes alone: Autoantibodies, no disease
Class II genes alone: Clinically silent (healthy)
Class I + Class II genes: autoimmune disease (e.g., SLE)
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lupus, but also because the structural requirements
for pathogenicity among autoantibodies will be
deciphered. This new knowledge, in turn, cannot
fail to influence the day-to-day clinical management
of the patient with systemic lupus erythematosus.
Questions and answers
DR. JORDAN J. COHEN: Do the renal lesions that
occur in NZB/NZW mice conform to the classifica-
tion scheme of renal disease in patients with SLE?
DR. SCHWARTZ: The usual lesion is diffuse lupus
nephritis.
DR. COHEN: Do all the mice develop diffuse le-
sions or is there a spectrum including mem-
braneous, focal, and other types of nephritis?
DR. SCHWARTZ: I will ask Dr. Janine André-
Schwartz whether lesions other than diffuse ones
occur in B/W mice.
DR. JAN INE ANDRE-SCHWARTZ: (Hematology-
Oncology Division, NEMCH): Yes. Limited focal
lesions have been described. Also, limited altera-
tions affecting either the glomerular basement mem-
brane and/or epithelial and endothelial cells can be
seen.
DR. COHEN: Is it reasonable to conclude from the
wide spectrum of renal lesions that occur in this
simple genetic model of SLE that the heteroge-
neous pattern of renal involvement observed clini-
cally is not necessarily an expression of genetic het-
erogeneity? A related question has to do with the
identical twins who develop SLE with renal in-
volvement. Does a given set of twins necessarily
develop the same kind of renal disease?
DR. SCHWARTZ: I don't know the answer to the
second question. It is a very interesting point and
should be looked into. As to the first question, I
would have to say that although the animal models
might seem genetically simple, they are in fact com-
plex. Considerable evidence indicates that numer-
ous genes are involved in both the immunologic ab-
normalities and the pathogenesis of the lesions. For
example, there are probably at least six genes that
determine the spontaneous hypersecretion of 1gM
by B cells of NZB mice (unpublished observations).
We are attempting to analyze the genetics of the
antibodies in the renal lesions with antiiodiotypic
antibodies. By this means we will try to estimate
how many families of antibodies are involved and
the nature of their binding specificities.
DR. COHEN: Are you suggesting that the morpho-
logic classification scheme that we currently use in
clinical diagnosis might be homologous with a clas-
sification structure based on the nature of the idio-
typic antibodies involved in the pathogenesis of the
renal damage?
DR. SCHWARTZ: It is too early to say that. I think
the present pathologic scheme is an excellent one
for clinical use because of its bearing on prognosis.
DR. COHEN: What is your hypothesis about the
heterogeneous nature of the renal lesions that occur
in patients who have lupus? Is it just a question of
how many immune complexes are deposited, or do
other factors explain why some patients develop
florid renal disease, others only moderate damage,
and others none at all?
DR. SCHWARTZ: Certainly the amount of immune
complexes deposited in the glomerulus must be a
factor. The immunoglobulin class also must be a
factor because some classes and even subtypes of
IgG fix complement, whereas other classes or sub-
types do not fix complement efficiently. Another
factor is the size of the immune complex. In experi-
mental models of serum sickness, large immune
complexes (those with a sedimentation coefficient
of 19) do not deposit in the kidney because they are
swept out of the circulation by the spleen and the
liver. By contrast, smaller complexes remain in the
circulation longer and are deposited more efficient-
ly on the glomerular basement membrane. The avi-
dity of the antibody for antigen also must be a fac-
tor. An equilibrium relationship exists between an-
tigen and the corresponding antibody; therefore
those antibodies that are highly avid for antigen
must be more prone to form stable immune com-
plexes than are less avid antibodies. The hypothesis
I presented is that each of these elements that con-
tribute to the lesions of lupus is under genetic con-
trol.
DR. JEROME P. KASSIRER: Is it likely that we
might be able to identify, either through genetic or
Environmental
antigen
Infectious agents,
immunogens,
drugs
Autoimmune disease
Autoantibody production
I mmunoinflammatory
disease
Fig. 9. Interactions among genes and environmental factors in
SLE.
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immunologic testing, which patients are more sus-
ceptible to serious complications and thus be in a
position to treat them earlier?
DR. SCHWARTZ: That is a possibility, but it is dif-
ficult to answer your question in a specific way.
Much is known about the mechanism of immune
complex deposition in the kidney, but what remains
unknown is the connection between those factors
and genes.
DR. KASSIRER: In Dr. Miller's familial study,
were there any hints about genetic transmission of
the particular kind of lupus that affected the pa-
tient?
DR. KENNETH MILLER (Hematology-Oncology
Division, NEMCH): No evidence for this was
found.
DR. ANDREW LEVEY (Renal Fellow, NEMCH):
Dr. Schwartz, given the genetic insights that you
have offered us, what do you mean when you say
some patients with SLE have been cured?
DR. SCHWARTZ: It is analagous to saying a pa-
tient who has a genetically determined cancer has
been cured. Let me stress again that we have to
think of lupus not only in genetic terms but also in
terms of hormones and the environment. These lat-
ter elements might be of considerable importance in
provoking the disease in a genetically susceptible
person; in this regard, SLE is similar to other ge-
netic diseases in which environment can contribute
to their manifestation. Deficiency of glucose-6-
phosphate dehydrogenase is a good example.
DR. COHEN: I assume that you would respond
similarly to a question about the episodic nature of
the clinical manifestations of SLE. Is it true that the
clinical manifestations can appear and resolve be-
cause of certain nongenetic factors?
DR. SCHWARTZ: Yes.
DR. AARON SPITAL (Renal Unit, Rhode Island
Hospital, Providence, Rhode Island): Much con-
troversy exists about the use of immunosuppressive
drugs for the treatment of lupus nephritis in view of
their obvious side effects. Indeed, today's patient is
a good illustration of these sequelae. I think many
people would have stopped immunosuppressive
treatment a long time before it was discontinued in
this patient. Do we know from animal models of this
disease whether these drugs alter the natural history
of lupus nephritis?
DR. SCHWARTZ: Yes. The (NZB X NZW)F1 hy-
brid mouse, which uniformly develops lupus ne-
phritis, has been tested extensively with cyclophos-
phamide and several other compounds, most of
which are therapeutically effective in this model
[29]. However, cyclophosphamide and azathioprine
have been shown to produce lymphomas in this
mouse model [30]. Information obtained from stud-
ies of chemotherapeutic agents in the (NZB x
NZW)FJ mouse has not been particularly useful
from the clinical point of view because, ironically,
such studies have been uniformally successful. This
point relates to Dr. Cohen's earlier question about
the uniformity of the renal lesion in such inbred ani-
mals. Perhaps this fact explains why such treatment
is highly successful in inbred mice, but why doubts
linger even today about its efficacy in genetically
heterogeneous humans.
DR. COHEN: Do you have any thoughts about the
role of plasmaphoresis in the treatment of lupus
nephritis?
DR. SCHWARTZ: Unless a prospective, con-
trolled, and rigorously designed clinical trial is per-
formed to evaluate the efficacy of plasmaphoresis,
we will be faced with yet another unproven mode of
treatment for this disease and, in this case, an ex-
ceedingly expensive one.
Reprint requests to Dr. R. Schwartz, Tufts University School
of Medicine Cancer Research Center, 136 Harrison Avenue,
Boston, Massachusetts 02111 USA
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